Compile Data Set for Download or QSAR
Report error Found 220 Enz. Inhib. hit(s) with all data for entry = 3162
TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393276(US9963434, Table 12.219 | 5-(3,4- difluorobenzenes...)
Affinity DataIC50: 16.2nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393246(US9963434, Table 12.189 | 5-(3-chloro-4- fluoroben...)
Affinity DataIC50: 19.6nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393274(US9963434, Table 12.217 | 5-(3- chlorobenzenesulfo...)
Affinity DataIC50: 39.5nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393080(US9963434, Table 12.26 | 5-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 61nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393273(US9963434, Table 12.216 | 5-(3-chloro-4- fluoroben...)
Affinity DataIC50: 87.8nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393074(US9963434, Table 12.20 | 5-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 108nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393097(US9963434, Table 12.42 | 6-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 108nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393275(US9963434, Table 12.218 | 5-(4- fluorobenzenesulfo...)
Affinity DataIC50: 137nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393277(US9963434, Table 12.220 | 5-(3-chloro-4- fluoroben...)
Affinity DataIC50: 169nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393194(US9963434, Table 12.137 | 5-(3-chloro-4- fluoroben...)
Affinity DataIC50: 180nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393059(US9963434, Table 12.6 | 5-(3-chloro-4- fluorobenze...)
Affinity DataIC50: 187nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393066(US9963434, Table 12.13 | 5-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 204nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393226(US9963434, Table 12.169 | 5-(3,4- difluorobenzenes...)
Affinity DataIC50: 219nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393206(US9963434, Table 12.149 | 5-(3,4- difluorobenzenes...)
Affinity DataIC50: 313nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393058(US9963434, Table 12.5 | 5-(3-chloro-4- fluorobenze...)
Affinity DataIC50: 347nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393268(US9963434, Table 12.211 | 5-(3,5- difluorobenzenes...)
Affinity DataIC50: 366nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393101(US9963434, Table 12.46 | 5-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 439nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393266(US9963434, Table 12.209 | 5-(3,4- dichlorobenzenes...)
Affinity DataIC50: 494nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393188(US9963434, Table 12.131 | 5-(3-chloro-4- fluoroben...)
Affinity DataIC50: 624nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393096(US9963434, Table 12.41 | 6-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 630nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393106(US9963434, Table 12.51 | 5-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 757nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393063(US9963434, Table 12.10 | 5-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 758nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393095(US9963434, Table 12.40 | 6-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 790nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393239(US9963434, Table 12.182 | 5-(3- chlorobenzenesulfo...)
Affinity DataIC50: 839nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393183(US9963434, Table 12.127 | 5-(3-chloro-4- fluoroben...)
Affinity DataIC50: 850nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393061(US9963434, Table 12.8 | 5-(3-chloro-4- fluorobenze...)
Affinity DataIC50: 929nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393176(US9963434, Table 12.120 | 5-(3-chloro-4- fluoroben...)
Affinity DataIC50: 1.02E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393271(US9963434, Table 12.214 | 5-(4-chloro-3- fluoroben...)
Affinity DataIC50: 1.02E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393203(US9963434, Table 12.146 | 5-(3- chlorobenzenesulfo...)
Affinity DataIC50: 1.04E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393204(US9963434, Table 12.147 | 5-(3-chloro-4- fluoroben...)
Affinity DataIC50: 1.10E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393123(US9963434, Table 12.68 | 5-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 1.25E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393136(US9963434, Table 12.81 | 5-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 1.69E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393103(US9963434, Table 12.48 | 5-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 1.70E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393083(US9963434, Table 12.28 | 5-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 1.95E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393143(US9963434, Table 12.88 | 5-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 2.00E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393104(US9963434, Table 12.49 | 5-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 2.10E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393192(US9963434, Table 12.135 | 5-(3-chloro-4- fluoroben...)
Affinity DataIC50: 2.18E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393098(US9963434, Table 12.43 | 5-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 2.40E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393187(US9963434, Table 12.130 | 5-(3-chloro-4- fluoroben...)
Affinity DataIC50: 2.43E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393146(US9963434, Table 12.91 | 5-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 2.55E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393175(US9963434, Table 12.119 | 5-(3-chloro-4- fluoroben...)
Affinity DataIC50: 2.83E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393228(US9963434, Table 12.171 | 5-(4- fluorobenzenesulfo...)
Affinity DataIC50: 2.84E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393142(US9963434, Table 12.87 | 5-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 3.02E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393105(US9963434, Table 12.50 | 5-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 3.09E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393041(US9963434, Table 12.2 | 5-(3-chloro-4- fluorobenze...)
Affinity DataIC50: 3.37E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393259(US9963434, Table 12.202 | N-[(2-methyl-1,3- thiazo...)
Affinity DataIC50: 3.77E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393233(US9963434, Table 12.176 | N-[(2-methyl-1,3- thiazo...)
Affinity DataIC50: 4.02E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393042(US9963434, Table 12.3 | 5-(3-chloro-4- fluorobenze...)
Affinity DataIC50: 4.59E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393180(US9963434, Table 12.124 | 5-(3-chloro-4- fluoroben...)
Affinity DataIC50: 4.84E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Luc Therapeutics

US Patent
LigandPNGBDBM393082(US9963434, Table 12.27 | 5-(3-chloro-4- fluorobenz...)
Affinity DataIC50: 5.51E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 220 total ) | Next | Last >>
Jump to: